![](/images/graphics-bg.png)
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
المؤلفون المشاركون
Davis, Keith L.
Côté, Isabelle
Kaye, James A.
Mendelson, Estella
Gao, Haitao
Perez Ronco, Julian
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-11-09
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population.
We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, observational review of anonymized US medical record data of patients diagnosed with IPSS low-risk (n=25) or intermediate-1-risk (n=83) MF.
The majority of patients were male (low risk, 60%; intermediate-1 risk, 69%).
Most patients (92% and 77%) were still receiving ruxolitinib at the medical record abstraction date (median observation/exposure time, 8 months).
The proportion of patients with moderate or severe palpable splenomegaly (≥10 cm) decreased from diagnosis (56%) to best response (12%).
Fatigue was reported in 47% of patients and was the most common constitutional symptom.
For most symptoms in both risk groups, shifts in the distribution of severity from more to less severe from diagnosis to best response were observed.
Both patients with low-risk and intermediate-1-risk MF experienced a substantial decrease in spleen size with ruxolitinib treatment in real-world settings.
For most symptoms examined, there were distinct improvements in the distribution of severity during ruxolitinib treatment.
These findings suggest that patients with lower-risk MF may benefit clinically from ruxolitinib treatment.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Davis, Keith L.& Côté, Isabelle& Kaye, James A.& Mendelson, Estella& Gao, Haitao& Perez Ronco, Julian. 2015. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Advances in Hematology،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1052448
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Davis, Keith L.…[et al.]. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Advances in Hematology No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1052448
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Davis, Keith L.& Côté, Isabelle& Kaye, James A.& Mendelson, Estella& Gao, Haitao& Perez Ronco, Julian. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Advances in Hematology. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1052448
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1052448
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)